We performed a systematic review and meta-analysis of randomized controlled trials comparing autologous hematopoietic cell transplantation (HCT) with other treatment modalities to analyze the risk for various secondary malignancies (SMs). Relative risks (RR) with 95% confidence intervals were estimated and pooled. Our search yielded 36 trials. The median follow-up was 55 (range 12-144) months. Overall, the RR for developing SMs was 1.23 ((0.97-1.55), I 2 = 4%, 9870 patients). Subgroup analysis of trials assessing TBI-containing preparative regimens and of patients with baseline lymphoproliferative diseases, showed there was a higher risk for SMs in patients given autografts (RR = 1.61 (1.05-2.48), I 2 = 14%, 2218 patients and RR = 1.62 (1.12-2.33), I 2 = 22%, 3343 patients, respectively). Among all patients, there was a higher rate of myelodysplastic syndrome MDS/AML in patients given HCT compared with other treatments (RR = 1.71 (1.18-2.48), I 2 = 0%, 8778 patients). The risk of secondary solid malignancies was comparable in the short term between patients given HCT and patients given other treatments (RR = 0.95 (0.67-1.32), I 2 = 0%, 5925 patients). We conclude that overall the risk of secondary MDS/AML is higher in patients given autologous HCT compared with other treatments. In the subgroup of patients given a TBI-based regimen and in those with a baseline lymphoproliferative disease, there was a higher risk of overall SMs.
INTRODUCTION
High dose chemo/radiotherapy with autologous hematopoietic cell transplantation (HCT) has been shown to be an effective therapy for a variety of hematologic and non-hematologic malignancies. However, it has become apparent as more patients survive both the disease and the early-post HCT period, that other potential long-term complications may hamper patients' prospects.
One complication that raises great concern is the possibility of developing a secondary malignancies (SM) following a successful treatment of the primary disease.
The estimated risk for SMs following autolgous HCT is 3.3 times higher compared with the risk in the general population 1 with incidences of secondary myelodysplastic syndrome (MDS)/AML and lymphoma of 5-20 and 10%, respectively.
2-5 While MDS and AML develop after several years (median 2.5 years), posttransplantation solid tumors have a longer latency time. 6 Factors such as age o 35 years, longer interval from diagnosis to HCT, 1 graft purging, 7 prior alkylator therapy and topoisomerase II inhibitors and higher doses of pre-transplant irradiation have been associated with higher incidence of SMs.
5, 8 However, it is not clear whether these factors apply explicitly to patients given autografts or to the general population treated with chemotherapy.
Thus, we aimed to perform a systematic review assembling all the available data retrieved from randomized controlled trials comparing the addition of autologous HCT with conventional chemotherapy and reporting long term secondary malignancies.
MATERIALS AND METHODS

Data sources
We conducted a comprehensive search strategy to identify both published and unpublished trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE (January 1966 and until 2013) .
We searched the following conference proceedings for trials in oncology and hematology (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) : the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), the American Society for Blood and Marrow Transplantation (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), and the International Society of Paediatric Oncology (SIOP). We searched the following trial databases for ongoing and unpublished trials: Current Controlled Trials in the metaRegister of controlled clinical trials and the National Institutes of Health Clinical Trials Registry. The references of all identified studies were inspected for more trials. Additionally, the corresponding author of each trial was contacted for information regarding unpublished trials or complementary information on their own trial.
We used the following search term: autologous transplantation and ([bone marrow] or 86 hematopoietic or [stem cell]). For MEDLINE, we added the Cochrane highly sensitive 87 search term for identification of clinical trials. 9 
Study selection
We included only randomized controlled trials. We included studies of patients undergoing autologous HCT for the treatment of hematological malignancies, solid tumors and non-malignant diseases (such as autoimmune diseases) that compared between autologous HCT and other treatment modalities. Trials were included irrespective of publication status, language and blinding.
We excluded trials of patients undergoing allogeneic HCT and trials that compared different preparative regimens prior to autologous HCT.
Data extraction and quality assessment
Two reviewers (IV and RR) independently inspected each reference identified by the search and applied the inclusion criteria. For possible relevant articles, the full article was obtained and inspected independently by the two reviewers. In the case of any disagreement between the two reviewers, a third reviewer extracted the data (AG-G). Data extraction was discussed, decisions were documented and, where necessary, the authors of the trials were contacted for clarification and complementary information on their trials.
Quality assessment
Trials fulfilling the inclusion criteria were assessed for methodological quality by two reviewers (IV and RR). This was done using the criteria described in the Cochrane Collaboration's tool for assessing risk of bias. 9 We separately assessed each domain and graded it as low risk of bias, unclear risk of bias or high risk of bias. In addition, sensitivity analyses were performed to assess the robustness of the findings to different aspects of the trial's methodology.
Definition of outcome
The primary outcome was the overall risk for secondary malignancies in patients undergoing autologous HCT compared with other treatment modalities. Secondary outcomes included the risk of two types of specific SM: secondary MDS/AML and secondary solid tumors. We aimed to evaluate these outcomes at the longest reported time point.
Comparisons
We defined the intervention as undergoing autologous HCT. The comparison intervention was defined as either no additional chemotherapy or conventional radiotherapy/chemotherapy (any therapy excluded high dose therapy and infusion of hematopoietic cells). Patients who were originally allocated to the non-transplant arm, and relapsed and were given salvaged autologous HCT were analyzed according to the intentionto-treat methodology based on the original allocated arm.
Data synthesis and analysis
Dichotomous data were analyzed by calculating the relative risk (RR) for each trial with 95% confidence intervals (CI) (Review Manager Version 5, Copenhagen, the Cochrane Collaboration, 2012). RRo1 favors the interventional arm (autologous HCT), that is. risk for secondary malignancies is lower in patients given autografts. For all outcomes, we performed an intention-to-treat analysis in which we included all known events in both nominator and denominator, even if excluded from the trial's original analysis. We assessed heterogeneity of trial results by calculating a χ 2 -test of heterogeneity and the I 2 measure of inconsistency. We used the MantelHaenszel fixed-effect model for pooling trial results unless statistically significant heterogeneity was found (Po0.10 or I 2 450%), in which case we used a random-effects model. Heterogeneity was investigated through subgroup and sensitivity analyses as defined above.
RESULTS
The search yielded 2229 potentially relevant trials, of which 74 were considered for further investigation. Of these, 41 studies were excluded of various reasons, Figure 1 . In addition, three abstract proceedings were identified and also included in the analysis. [10] [11] [12] Overall 36 trials, enrolling 9870 patients, conducted between the years 1987 and 2011 fulfilled the inclusion criteria. One trial reported on two cohorts of patients and for the sake of report and analysis was considered as two separate trails. The median follow-up was 55 (range 12-144) months. The median time of follow-up was 45 years in 17 trials, 3-5 years in 15 trials and o3 years in 4 trials.
HCT was given for the treatment of lymphoproliferative diseases (16 trials), [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 29, 30, 32 solid malignancies (16 trials) 25, 27, 28, 31, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] and plasma cell disorders [10] [11] [12] 26 (4 trials). Two trials used purged autografts as the graft source. 7, 19 In the comparative arm (the non-transplant arm), the regimens were either observation (5 trials) or various standard radio/ chemotherapy (31 trials). Table 1 depicts the characteristics of included trials. Table 2 depicts the risk of bias assessment. Overall, the quality of included trials was moderate. Random sequence generation was adequate in 14 trials and unclear in 22 trials. Allocation concealment was adequate in 23 trials and unclear in 13 trials. All trials reported data according to the intention-to-treat principle and were considered as a low risk of bias.
Primary outcome-overall secondary malignancies Overall, there was no difference in the risk of secondary malignancies between patients that received autotransplant and the comparative arm (RR = 1.23 (95% CI 0.97-1.55), I 2 = 4%, 36 trials, 9870 patients), Figure 2 . Subgroup analysis according to the comparative arm showed similar results when the autologous arm was compared with observation only or to other therapies (RR = 2.73 (95% CI 0.97-7.68), I 2 = 0%, 5 trials, 722 patients and RR = 1.2 (95% CI 0.95-1.52), I 2 = 12%, 31 trials, 9409 patients, respectively).
Among the subgroup of patients with lymphoproliferative diseases there was a higher risk of secondary malignancies in patients given autografts compared with the other group (RR = 1.62 (95% CI 1.12-2.33), I 2 = 22%, 16 trials, 3343 patients), Figure 2 . When we excluded the two trials in which patients received purged grafts, the overall risk of secondary malignancies was similar between the two groups (RR = 1.16 (95% CI 0.78-1.72), I 2 = 0%, 14 trials, 3009 patients). Subgroup analyses of patients with plasma cell disorders and solid malignancies showed similar risks of secondary malignancies between patients who were given or not given autografts ((RR = 2.02 (95% CI 0.62-6.66), I 2 = 0%, 4 trials, 706 patients) and (RR = 0.97 (95% CI 0.71-1.32), I 2 = 9%, 16 trials, 5821 patients), respectively)), Figure 2 . In the subgroup analysis of studies given TBI-containing preparative regimens prior to autografts, there was a higher risk of secondary malignancies in patients given autografts (RR = 1.61 (95% CI 1.05-2.48), I 2 = 14%, 9 trials, 2218 patients), Figure 3 . When analyzing, among the lymphoproliferative diseases group, only the patients given TBI-containing regimen, there was a higher risk of secondary malignancies in patients given autografts compared with the other group (RR = 1.64 (95% CI 1.05-2.57), I 2 = 32%, 7 trials, 1675 patients), while in the subgroup of patients given non-TBI containing regimens the risk for SM was similar between the 2 groups (RR = 1.58 (95% CI 0.85-2.94), I 2 = 21%, 9 trials, 1668 patients).
Sensitivity analysis according to quality of studies including studies with a lower risk of bias according to allocation concealment, random sequence generation and studies reporting complete outcome data showed similar risks of overall SM between patients who were given autoglous HCT and those not given (RR = 1.12 (95% CI 0.85-1.48), I 2 = 21%, 23 trials, 5680 patients; RR = 1.24 (95% CI 0.85-1.82), I 2 = 0%, 14 trials, 3292 patients; RR = 1.17 (95% CI 0.93-1.48), I 2 = 11%, 32 trials, 9180 patients, respectively).
Secondary outcomes-specific secondary malignancies Secondary MDS/AML. Overall there was a higher risk for MDS/ AML in patients receiving autografts compared with patients given other therapies (RR = 1.71 (95% CI 1.18-2.48), I 2 = 0%, 33 trials, 8778 patients), Figure 4 . Among the subgroup of patients with lymphoproliferative diseases there was a higher risk of MDS/ AML in patients given autografts compared with the other group (RR = 2.35 (95% CI 1.36-4.05), I 2 = 0%, 16 trials, 3090 patients). This was also true after excluding the two studies in which patients were given purged grafts (RR = 1.83 (95% CI 1.01-3.29), I 2 = 0%, 14 trials, 2756 patients). Among both plasma cell disorders and solid malignancies, there was no difference between the groups (RR = 1.41 (95% CI 0.28-7.08), I 2 = 0%, 3 trials, 304 patients and RR = 1.24 (95% CI 0.72-2.15), I 2 = 8%, 14 trials, 5384 patients, respectively).
Subgroup analysis according to TBI-containing regimens prior to autologous HCT showed that both in patients given TBIcontaining regimens and in non-TBI containing regimens there was a higher risk of secondary MDS/AML in patients given autografts compared with patients not given autografts, albeit risk was higher in patients given a TBI-containing regimen (RR = 1.98 Abbreviations: BEAC = BCNU, etoposide, cytarabine; CBV = CY, BCNU, etoposide, CY; CEP = CY, etoposide, cisplastin; f/u = follow-up; MM = multiple myeloma; NR = not reported; NHL = Non-Hodgkin's lymphoma; SM = secondary malignancy; STAMP I = CY, cisplastin, carmustine; STAMP V = CY, carboplatin; thiotepa.
Secondary cancers post autotransplant I Vaxman et al (95% CI 1.02-3.83), I 2 = 0%, 9 trials, 2188 patients and RR = 1.60 (95% CI 1.02-2.50), I 2 = 0%, 9 trials, 6590 patients, respectively). Subgroup analysis of patients given autografts vs observationonly showed a higher risk of MDS/AML in patients allocated to autologous HCT (RR = 3.76 (95% CI 1.10-12.87), I 2 = 0%, 5 trials, 692 patients). When we analyzed the subgroup of patients given autografts compared with chemotherapy/radiotherapy therapies there was also a higher risk of MDS/AML in patients given autografts (RR = 1.56 (95% CI 1.06-2.31), I 2 = 0%, 26 trials, 8086 patients).
Subgroup analysis according to the median period of follow-up (o 3 years, 3-5 years and 45 years) showed that in the patients with lymphoproliferative diseases in both 3-5 years and 45 years there was higher incidence of secondary MDS/AML (RR = 2.31 (95% CI 1.03-5.14), I 2 = 0%, 7 trials, 1455 patients and RR = 2.38 (95% CI 1.14-5), I 2 = 0%, 8 trials, 1405 patients, respectively). In patients with plasma cell disorders with a median follow-up period of o 3 years and 3-5 years there were similar risks of secondary MDS/AML between the 2 groups (RR = 3 (95% CI 0.13-69), 1 trial, 40 patients and RR = 1.01 (95% CI 0.14-7.14), I 2 = 0%, 2 trials, 264 patients, respectively). Of note, none of the trials had a median follow-up period 45 years. In patients with solid malignancies with a median follow-up period 3-5 years there were similar risks for secondary MDS/AML between the 2 groups (RR = 1.29 (95% CI 0.32-5.18), I 2 = 0%, 2746 patients, 6 trials); however at a median follow-up 45 years there was a higher incidence of secondary MDS/AML in patients given autografts compared with other treatment options (RR = 2.48 (95% CI 1.17-5.25), I 2 = 0%, 9 trials, 2113 patients). Sensitivity analysis according to quality of studies including studies with a lower risk of allocation concealment, lower risk of random sequence generation and studies reporting complete outcome data showed a higher risk of MDS/AML in patients given autoglous HCT compared with those not given (RR = 2 = 0%, 6 trials, 1185 patients). Subgroup analyses according to the median period of follow-up showed comparable risks between the two groups.
DISCUSSION
Our systematic review compiled all published randomized controlled trials assessing the risk of secondary malignancies in patients given autologous HCT, and showed that overall there was no higher risk of secondary malignancies in patients given autografts compared with patients allocating to other treatments. However, in the subgroup of patients given a TBI-based regimen and in those with a baseline lymphoproliferative disease, there was a higher risk of secondary malignancies.
When we focused only on secondary MDS/AML, the risk was increased for the whole cohort, in the subgroup of patients with lymphoproliferative diseases who were given autologous HCT and in patients with solid malignancies (only in trials with 45 years of follow-up). There was no increase in secondary solid malignancies in patients given autologous HCT compared with other treatment modalities; however, for this outcome the follow-up period was relatively short.
Autologous HCT has been shown to be associated with prolongation of both PFS and OS in patients with lymphoproliferative diseases and plasma cell disorders. However, the utilization of a more intensive therapy may be associated with subsequent secondary malignancies.
We showed that when comparing patients given autologous HCT to patients allocating to other treatments, the overall risks of secondary malignancies were comparable. We hypothesize that the fact that both arms (transplant and non-transplant) contained high doses of anthracyclines and topoisomerase II inhibitors, contributed to the relatively even risks of developing secondary malignancies in both arms. 5 Interestingly although this did not reach statistical significance, the RR for secondary malignancies was higher in the comparison of transplant arm vs observation only and was lower in the comparison of transplant arm vs non-observational treatments.
We found that baseline disease may interact with the risk of secondary malignancies after autologous HCT. Patients with lymphoproliferative diseases that received autologous HCT had Conversely, patients treated due to solid malignancies or plasma cell disorders that were given autografts were not at a higher risk of overall or specific secondary malignancies. However, when we performed a subgroup analysis according to the median period of follow-up, we did find that after at least 5 years, patients with solid malignancies given autografts may be at a higher risk of secondary MDS/AML.
As stated above, we did not find a higher risk of secondary solid tumors among all the analyzed subgroups. However, as the latency period for solid malignancies may be prolonged and the median follow-up period of all studies was only 55 months, one may presume that after a sufficient follow-up time, 45 years, an increase in the risk of secondary tumors may be seen among patients given autografts.
The higher risk of secondary malignancies in patients with lymphoproliferative diseases was shown in a large survey of the EBMT, calculating the rate of secondary MDS/AML in patients with lymphoproliferative diseases to be 5% at 5 years after HCT, 45 which was higher than the rate reported in non-transplant patients. 46 In addition, a recent a retrospective study suggested that the rate of secondary MDS/AML is correlated with the intensity of the regimen. 46 There are two main types of secondary MDS/AML-one is associated with topoisomerase II inhibitors, and usually occurs at a lag of 2-3 years from exposure, and the second is associated with previous exposure to radiation and alkylating agents, and usually occurs later, 5-7 years after therapy. 47 Thus, as we showed in the subgroup of patients with baseline solid malignancies, only in studies reporting outcomes after 45 years (in which patients were given mostly alkylator-based regimens) there was association between autologous HCT and subsequent secondary MDS/AML.
We identified TBI (given in all studies at a cumulative dose 410 Gy) among the whole cohort as a risk factor for both overall secondary malignancies and for secondary MDS/AML. In patients with lymphoma, radiation therapy has been considered as the most significant risk factor for developing secondary solid tumors, with the majority of secondary cancers arising either within or at the edges of radiation fields. 48, 49 In addition, TBI-containing regimens have been previously associated with a major impact on the incidences of secondary MDS/AML in patients given autografts. 45, 47 Several limitations of our study merit consideration. The included studies were heterogeneous regarding the type of patients, type of baseline diseases, the chemotherapy regimens and the conditioning protocols. To address this limitation, we performed subgroup analyses according to various domains to identify specific groups that are at a higher risk for secondary malignancies. In most of the studies the question of secondary malignancies was not specifically addressed as primary or secondary endpoints, thus potentially introducing incomplete data collection bias. To address this limitation, we performed sensitivity analyses in which we included only studies of high quality (low risk of bias) that reported complete data.
Last, the follow-up period in the majority of the trials was not sufficient to address the question of secondary malignancies, specifically when considering secondary solid malignancies. Thus, with a prolonged follow-up, results may change.
To conclude, we showed that the risk of secondary MDS/AML is increased after autologous HCT for treating lymphoproliferative malignancies and possibly also for treating solid malignancies. Lacking sufficient follow-up period, studies with a long-term follow-up are necessary to adequately evaluate the association between autologous HCT and secondary solid malignancies.
When deciding to perform an autologous HCT in a patient, clinicians should balance the risks and the benefits. While taking into account the potential efficacy and long-term survival benefit of autologous HCT, considering the long-term risks such as secondary malignancies influenced by individual and therapy-related risk factors, a tailoring approach can be optimized.
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